Medicare Beneficiaries Can Now Access Wegovy® for Obesity Management with New $50 Copay
On July 1, 2026, a significant advancement was inaugurated for many older Americans battling obesity with the introduction of the Medicare GLP-1 Bridge program. This program is designed to facilitate access to Wegovy®, a groundbreaking medication developed to treat obesity and reduce the risks associated with cardiovascular diseases. Eligible Medicare beneficiaries can now obtain Wegovy® (semaglutide), both in injection and pill form, for a mere monthly copay of $50. Wegovy® isn’t just any weight management drug; it’s the only one that has received FDA approval for reducing risks of major heart events like heart attacks and strokes in adults with both obesity and heart disease. This is particularly critical for individuals aged 65 and older, many of whom face significant health challenges linked to both conditions.
Since its launch back in January 2026, Wegovy® has reportedly achieved over 3 million prescriptions, underscoring its growing acceptance and effectiveness in managing obesity. With the new Medicare GLP-1 Bridge, this access pathway aims at making authentic, FDA-approved Wegovy® available to more patients, thus improving treatment outcomes and overall health profiles for those affected by obesity.
Jamey Millar, Executive Vice President of US Operations at Novo Nordisk, emphasized the importance of this moment, stating, "For many older Americans living with obesity, this is a moment they and their families have been waiting for. The Medicare GLP-1 Bridge program offers a new, affordable path to an FDA-approved treatment that was previously not covered.” This sentiment resonates deeply within the community of Medicare beneficiaries who have long struggled to obtain effective treatment options for obesity.
To utilize the Medicare GLP-1 Bridge, eligible patients are advised to follow a straightforward procedure:
1. Consult with Your Doctor: The first step is to have a detailed discussion with your healthcare provider about whether Wegovy® is a suitable option for you and to check your eligibility for the Medicare GLP-1 Bridge.
2. Prescription and Prior Authorization: If deemed appropriate, your doctor will prescribe Wegovy® and complete the necessary prior authorization processes required by Medicare on your behalf.
3. Medication Collection: After the prescription is processed, patients can pick up their medication from their pharmacy, paying $50 for a one-month supply. Once established, refills can continue without requiring new prior authorization, as long as the same GLP-1 medication is being utilized.
It’s essential to note that Wegovy® will still be accessible through Part D benefits for other approved indications, guaranteeing additional options for eligible beneficiaries. This initiative has sparked hope within the community, with advocates like Joe Nadglowski, President of the Obesity Action Coalition, stating, “This program offers new hope for Medicare beneficiaries who may finally be able to access obesity medications at an affordable cost.”
In addition, Novo Nordisk is dedicated to supporting the program's rollout by collaborating closely with healthcare providers, pharmacists, and patient advocacy groups to ensure patients receive adequate resources and guidance throughout the medication request process.
As a leader in the GLP-1 medication category, Novo Nordisk is prioritizing access to authentic, FDA-approved medications while actively working to prevent patients from resorting to unsafe alternatives. This commitment extends through various initiatives aimed at enhancing patient access to essential health care.
For those looking for support or needing further information regarding the Medicare GLP-1 Bridge, the NovoCare® Obesity and Medicare GLP-1 Bridge Support Team is ready to assist at 1-888-809-3942, and additional updates can be found on the Wegovy® official website.
In conclusion, the implementation of the Medicare GLP-1 Bridge marks a pivotal moment in the quest for effective obesity management for Medicare beneficiaries, bringing hope and a much-needed financial relief to those confronting this chronic disease. With accessibility to Wegovy®, many individuals can now embark on their journey toward better health, moving closer to effective management of obesity and related health conditions.
Since its launch back in January 2026, Wegovy® has reportedly achieved over 3 million prescriptions, underscoring its growing acceptance and effectiveness in managing obesity. With the new Medicare GLP-1 Bridge, this access pathway aims at making authentic, FDA-approved Wegovy® available to more patients, thus improving treatment outcomes and overall health profiles for those affected by obesity.
Jamey Millar, Executive Vice President of US Operations at Novo Nordisk, emphasized the importance of this moment, stating, "For many older Americans living with obesity, this is a moment they and their families have been waiting for. The Medicare GLP-1 Bridge program offers a new, affordable path to an FDA-approved treatment that was previously not covered.” This sentiment resonates deeply within the community of Medicare beneficiaries who have long struggled to obtain effective treatment options for obesity.
To utilize the Medicare GLP-1 Bridge, eligible patients are advised to follow a straightforward procedure:
1. Consult with Your Doctor: The first step is to have a detailed discussion with your healthcare provider about whether Wegovy® is a suitable option for you and to check your eligibility for the Medicare GLP-1 Bridge.
2. Prescription and Prior Authorization: If deemed appropriate, your doctor will prescribe Wegovy® and complete the necessary prior authorization processes required by Medicare on your behalf.
3. Medication Collection: After the prescription is processed, patients can pick up their medication from their pharmacy, paying $50 for a one-month supply. Once established, refills can continue without requiring new prior authorization, as long as the same GLP-1 medication is being utilized.
It’s essential to note that Wegovy® will still be accessible through Part D benefits for other approved indications, guaranteeing additional options for eligible beneficiaries. This initiative has sparked hope within the community, with advocates like Joe Nadglowski, President of the Obesity Action Coalition, stating, “This program offers new hope for Medicare beneficiaries who may finally be able to access obesity medications at an affordable cost.”
In addition, Novo Nordisk is dedicated to supporting the program's rollout by collaborating closely with healthcare providers, pharmacists, and patient advocacy groups to ensure patients receive adequate resources and guidance throughout the medication request process.
As a leader in the GLP-1 medication category, Novo Nordisk is prioritizing access to authentic, FDA-approved medications while actively working to prevent patients from resorting to unsafe alternatives. This commitment extends through various initiatives aimed at enhancing patient access to essential health care.
For those looking for support or needing further information regarding the Medicare GLP-1 Bridge, the NovoCare® Obesity and Medicare GLP-1 Bridge Support Team is ready to assist at 1-888-809-3942, and additional updates can be found on the Wegovy® official website.
In conclusion, the implementation of the Medicare GLP-1 Bridge marks a pivotal moment in the quest for effective obesity management for Medicare beneficiaries, bringing hope and a much-needed financial relief to those confronting this chronic disease. With accessibility to Wegovy®, many individuals can now embark on their journey toward better health, moving closer to effective management of obesity and related health conditions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.